Login
Sign up

[ARS] Xenetic Biosciences, Inc. SEC Filing

Filing Impact

(No impact)

Filing Sentiment

(Neutral)

Form Type

ARS

10/31/2025 - 04:30 PM

ARS - Xenetic Biosciences, Inc.

ARS Filing - Xenetic Biosciences, Inc.

This filing is available as a PDF document.

Filing Type: ARS

Company: Xenetic Biosciences, Inc. (XBIO)

Acceptance Date: 2025-10-31T16:30:06.000Z

View PDF Document

Source: View Original Filing on SEC EDGAR

Xenetic Biosciences Inc

NASDAQ:XBIO

XBIO Rankings

#6383 Ranked by Market Cap

N/A Ranked by Dividends

XBIO Latest News

Oct 10, 2025

Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock

Aug 13, 2025

Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results

Jul 30, 2025

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma

Jul 23, 2025

Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

Jul 8, 2025

Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

XBIO Latest SEC Filings

Oct 31, 2025

[DEF 14A] Xenetic Biosciences, Inc. Definitive Proxy Statement

Oct 10, 2025

[424B5] Xenetic Biosciences, Inc. Prospectus Supplement (Debt Securities)

Oct 14, 2025

[8-K] Xenetic Biosciences, Inc. Reports Material Event

Oct 10, 2025

[424B5] Xenetic Biosciences, Inc. Prospectus Supplement (Debt Securities)

Aug 13, 2025

[8-K] Xenetic Biosciences, Inc. Reports Material Event

XBIO Stock Data

Market Cap 7.49M

Float 2.04M

Insiders Ownership 19.06%

Institutions Ownership 4.6%

Short Percent 1.43%

Industry Biotechnology

Sector Pharmaceutical Preparations

Website Link

Country United States

City FRAMINGHAM